Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Breast Neoplasms 6397Neoplasms 5369Prostatic Neoplasms 2966Carcinoma, Non-Small-Cell Lung 2709Colorectal Neoplasms 2679Lung Neoplasms 2269Multiple Myeloma 1663Lymphoma 1600Neoplasm Metastasis 1554Leukemia, Myeloid, Acute 1540Melanoma 1486Pancreatic Neoplasms 1470Ovarian Neoplasms 1424Leukemia 1389Head and Neck Neoplasms 1284Precursor Cell Lymphoblastic Leukemia-Lymphoma 1283Lymphoma, Non-Hodgkin 1231Colonic Neoplasms 1160Carcinoma, Hepatocellular 1142Stomach Neoplasms 1130Leukemia, Lymphocytic, Chronic, B-Cell 1090Brain Neoplasms 1053Rectal Neoplasms 980Lymphoma, Follicular 979Recurrence 978Uterine Cervical Neoplasms 927Glioblastoma 921Carcinoma, Renal Cell 883Lymphoma, Large B-Cell, Diffuse 854Hodgkin Disease 777

Interventions

continuous erythropoietin receptor activator 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Renal Anemia × Clear all
NCT00717366 2017-09-08

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Hoffmann-La Roche

Phase 2 Completed
64 enrolled 15 charts 1 FDA
Classical hematology

Renal Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡